Leverage a range of research and development solutions to improve the productivity of oncology drug development

Clinically Relevant Lung Cancer PDX Cohort Screening Opportunity Enrollment Ends Nov 30th

Large scale syngeneic screening opportunity across 6 lines Enrollment ends Oct 31

Large-Scale in vitro screening opportunity of primary AML models with reduced cost

Learn more about humanized mouse models for the preclinical evaluation of novel immunotherapies

Identify PDX cohorts based on molecular characteristics, patient treatment, standard-of-care testing outcomes, clinical features and more